All Stories

  1. How to make sense of a Cochrane systematic review
  2. Maintenance treatment for adults with chronic asthma
  3. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis
  4. Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews
  5. Holding chambers (spacers) versus nebulisers for beta‐agonist treatment of acute asthma
  6. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
  7. Illustrating risk vs benefit with the tiotropium Respimat inhaler
  8. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
  9. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
  10. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children
  11. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events
  12. Vaccines for preventing influenza in people with asthma
  13. Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews
  14. Inhaled corticosteroids in COPD: quantifying risks and benefits
  15. Explaining the benefits of statins
  16. The Cochrane Library and safety of regular long‐acting beta2‐ agonists in children with asthma: an overview of reviews
  17. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews
  18. Ionisers for chronic asthma
  19. Alexander technique for chronic asthma
  20. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease
  21. Overview of the safety of regular formoterol or salmeterol in children with asthma
  22. Hospital at home in chronic obstructive pulmonary disease: Is it a viable option?
  23. Regular treatment with formoterol for chronic asthma: serious adverse events
  24. Anticholinergic therapy for acute asthma in children
  25. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease
  26. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events
  27. Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease
  28. Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease
  29. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2 -agonists for chronic obstructive pulmonary disease
  30. Safety of tiotropium
  31. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
  32. Bronchodilator treatment and asthma death: A new analysis of a British case-control study
  33. Combination formoterol and inhaled steroid as maintenance and reliever therapy versus higher dose combination inhaler maintenance for chronic asthma in adults and children
  34. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
  35. The added effect of inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease
  36. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease
  37. Nebulisers versus hand-held inhalers to deliver beta2-agonist bronchodilator drugs in non-acute asthma
  38. Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
  39. Cochrane review: Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
  40. Combination inhaled steroid and long-acting beta-agonist in addition to tiotropium versus tiotropium alone for chronic obstructive pulmonary disease
  41. Quality-improvement strategies for the management of hypertension in chronic kidney disease in primary care: a systematic review
  42. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
  43. Home-based educational interventions for children with asthma
  44. Formoterol versus short-acting beta-agonists as relief medication for chronic asthma
  45. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events
  46. Caffeine for asthma
  47. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events
  48. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults
  49. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events
  50. Combination inhaled steroid and long-acting beta-agonist versus tiotropium for chronic obstructive pulmonary disease
  51. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events
  52. Regular fixed-dose treatment with formoterol and inhaled corticosteroids versus regular treatment with salmeterol and inhaled corticosteroids for chronic asthma: serious adverse events
  53. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
  54. Culture-specific programs for children and adults from minority groups who have asthma
  55. Combination formoterol and inhaled steroid versus beta2 -agonist as relief medication for chronic asthma in adults and children
  56. Culture-specific programs for children and adults from minority groups who have asthma
  57. Regular treatment with formoterol for chronic asthma: serious adverse events
  58. Fluticasone at different doses for chronic asthma in adults and children
  59. Fluticasone versus placebo for chronic asthma in adults and children
  60. The use of combined inhalers in asthma
  61. Regular treatment with salmeterol for chronic asthma: serious adverse events
  62. Combination formoterol and inhaled steroid as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
  63. Vaccines for preventing influenza in people with asthma
  64. Combination inhaled steroid and long-acting beta-agonist versus fast-acting beta agonist as relief medication for chronic asthma in adults and children
  65. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults
  66. Regular treatment with formoterol for chronic asthma: serious adverse events
  67. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
  68. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events
  69. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
  70. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children
  71. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
  72. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease
  73. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease
  74. Reply
  75. Misuse of confidence intervals threatens conclusions
  76. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
  77. Regular treatment with salmeterol for chronic asthma: serious adverse events
  78. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma
  79. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
  80. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease
  81. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
  82. Fluticasone versus 'extrafine' HFA-beclomethasone dipropionate for chronic asthma in adults and children
  83. Holding chambers versus nebulisers for inhaled steroids in chronic asthma
  84. Influenza vaccine for patients with chronic obstructive pulmonary disease
  85. Dummies and SIDS: Low response rates generate considerable uncertainty
  86. Vaccines for preventing influenza in people with asthma
  87. Spacers and nebulisers for the delivery of beta-agonists in non-life-threatening acute asthma
  88. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma
  89. Ionisers for chronic asthma
  90. Educational interventions for asthma in children
  91. Triptan medications to treat acute migraine
  92. The lowering of blood pressure after stroke
  93. Authors should make their data available
  94. Extracts from "Clinical Evidence": Chronic asthma
  95. Travel and risk of venous thrombosis
  96. Holding chambers versus nebulisers for inhaled steroids in chronic asthma
  97. A paper that changed our practice: Which postcoital contraceptive?
  98. Care is required with cost effectiveness approach
  99. Alexander technique for chronic asthma
  100. Screening mammography re-evaluated
  101. Overlooking of Cochrane reviews in asthma research
  102. Nebulisers versus hand-held inhalers to deliver beta2-agonist bronchodilator drugs in non-acute asthma
  103. Reducing antibiotic use in children with acute otitis media
  104. Confidence intervals for the number needed to treat
  105. Teaching patients with bipolar disorder to identify early symptoms of relapse
  106. Personal stereos and hearing loss